Myrcludex B Preliminary results are expected in June 2014. Read the following article.
http://www.prnewswire.com/news-releases/maxwell-biotech-venture-funds-portfolio-company-hepatera-completes-enrollment-of-phase-iia-clinical-trial-of-myrcludex-b-for-hbv-248734041.html